Shareholders Approve 1 Million Share Increase for Equity Incentive Plan
Summary
Astrana Health shareholders approved an amendment to its 2024 Equity Incentive Plan, increasing the shares reserved for issuance by 1 million, which represents approximately 1.8% potential dilution.
Key Events
-
Equity Incentive Plan Approved
Shareholders approved the Amended and Restated 2024 Equity Incentive Plan at the Annual Meeting held on June 10, 2026.
-
Share Reserve Increased
The number of shares reserved for issuance under the 2024 Plan was increased by 1,000,000 shares, representing approximately 1.8% potential dilution based on current outstanding shares.
-
Plan Term Extended
The term of the 2024 Plan was extended until March 24, 2036.
-
Routine Annual Meeting Approvals
Shareholders also elected nine directors, ratified the appointment of Ernst & Young LLP as the independent auditor, and approved executive compensation on an advisory basis.
Analysis
Astrana Health shareholders approved an amendment to the 2024 Equity Incentive Plan, increasing the shares reserved for issuance by 1 million. This authorization, representing approximately 1.8% potential dilution, provides the company with additional capacity for employee compensation and retention. While dilutive, such plans are a standard tool for motivating and retaining talent, especially for a company that has recently reported strong financial results and is trading near its 52-week high.
At the time of this filing, ASTH was trading at $38.73 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $18.08 to $39.93. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.